pyrazinamide and rifapentine

pyrazinamide has been researched along with rifapentine in 32 studies

Research

Studies (32)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (3.13)	18.7374
1990's	4 (12.50)	18.2507
2000's	9 (28.13)	29.6817
2010's	15 (46.88)	24.3611
2020's	3 (9.38)	2.80

Authors

Authors	Studies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Bismuth, R; Grosset, J; Lecoeur, H; Truffot-Pernot, C	1
Chapuis, L; Grosset, JH; Ji, B; O'Brien, RJ; Raviglione, MC; Truffot-Pernot, C	1
Chan, SL; Kam, KM; Lam, CW; Leung, CC; Mitchison, DA; Morris, JS; Tam, CM	1
Chase, SE; Chmielewski, AJ; Cynamon, MH; Lenaerts, AM	1
Daniel, N; Geiter, LJ; Grosset, J; Hejblum, G; Ji, B; Lounis, N; O'Brien, RJ; Szpytma, M; Truffot-Pernot, C; Vernon, A	1
Arnadottir, T; Enarson, DA; Rieder, HL; Trébucq, A	1
Chu, N; Yan, B; Zhu, L	1
Chan, SL; Goodall, RL; Kam, KM; Mitchison, DA; Tam, CM	1
Barnes, GL; Chaisson, RE; Coberly, JS; Falco, G; Faulhaber, JC; Moore, RD; Schechter, M; Zajdenverg, R	1
Bishai, WR; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, K	1
Burman, WJ	1
Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M	1
Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M	1
Andries, K; Chauffour, A; Ibrahim, M; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N	1
Lange, C; Leung, CC; Rieder, HL; Yew, WW	1
Andries, K; Gevers, T; Lounis, N	1
Ahmad, Z; Almeida, DV; Converse, PJ; Grosset, JH; Li, SY; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Zhang, M	1
Amoabeng, O; Andries, K; Mdluli, KE; Minkowski, A; Nuermberger, EL; Peloquin, CA; Taylor, D; Wallis, RS; Williams, K	1
Dutta, NK; Grosset, JH; Illei, PB; Karakousis, PC; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Pinn, ML	1
Almeida, D; Grosset, JH; Karakousis, PC; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tasneen, R; Zhang, M	1
Abubakar, I; Harris, RJ; Lipman, MC; Muñoz, L; Stagg, HR; Zenner, D	1
Bateson, AL; Butcher, PD; Charalambous, S; Churchyard, GJ; Clouting, HE; Coleman, D; Geldenhuys, H; Harrison, TS; Hatherill, M; Jindani, A; Magweta, L; McHugh, TD; McIlleron, HM; Mitchison, DA; Mungofa, S; Nunn, AJ; Nyirenda, S; Phillips, PP; Shah, NA; Shepherd, J; van Dijk, JH; Zizhou, S; Zvada, SP	1
Barnes, GL; Carman, D; Chaisson, RE; Dawson, R; Dorman, SE; Efron, A; Gupte, N; Hoffman, J; McIlleron, H; Narunsky, K; Whitelaw, A	1
Hamilton, CD; Holland, DP; Stout, JE	1
Armstrong, DT; Barnes, GL; Cavalcante, SC; Chaisson, RE; Cohn, S; Conde, MB; Dalcolmo, M; Dooley, KE; Dorman, SE; Duarte, RS; Durovni, B; Efron, A; Loredo, C; Marzinke, MA; Mello, FC; Moulton, LH; Rolla, V; Savic, RM	1
Li, L; Sun, XW; Wang, Z; Xiao, H; Zhang, CL; Zhang, H	1
Bax, HI; de Knegt, GJ; de Steenwinkel, JEM; Mourik, BC; Simonsson, USH; Svensson, RJ; Verbon, A	1
Ignatius, EH; Swindells, S	1
Allen, L; Carr, W; Goswami, N; Kurbatova, E; Starks, A; Winston, C	1
Chen, X; Feng, Z; Ge, S; Li, R; Li, Y; Miao, Y; Peng, Y; Song, L; Sun, F; Wang, X; Zhang, W; Zhang, Y	1

Reviews

4 review(s) available for pyrazinamide and rifapentine

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Treatment of latent infection with Mycobacterium tuberculosis: update 2010. The European respiratory journal, 2011, Volume: 37, Issue:3 Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Communicable Disease Control; Drug Design; Drug Resistance, Bacterial; Female; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Male; Mycobacterium tuberculosis; Patient Compliance; Pyrazinamide; Rifampin; Treatment Outcome	2011
Treatment of latent tuberculosis infection: a network meta-analysis. Annals of internal medicine, 2014, Sep-16, Volume: 161, Issue:6 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Pyrazinamide; Rifampin	2014
Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB. Current HIV/AIDS reports, 2020, Volume: 17, Issue:6 Topics: Anti-HIV Agents; Antitubercular Agents; Drug Interactions; Extensively Drug-Resistant Tuberculosis; HIV Infections; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary	2020

Trials

9 trial(s) available for pyrazinamide and rifapentine

Article	Year
Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. American journal of respiratory and critical care medicine, 1998, Volume: 157, Issue:6 Pt 1 Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Pyrazinamide; Rifampin; Streptomycin; Treatment Outcome; Tuberculosis, Pulmonary	1998
[Controlled clinical trial on efficacy of 5-month regimens and whole course intermittent 6-month regimens in treating bacillary pulmonary tuberculosis]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 1998, Volume: 21, Issue:7 Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Mycobacterium tuberculosis; Pyrazinamide; Recurrence; Rifampin; Sputum; Tuberculosis, Pulmonary	1998
Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2002, Volume: 6, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Therapy, Combination; Female; Hong Kong; Humans; Isoniazid; Life Tables; Male; Middle Aged; Prognosis; Proportional Hazards Models; Pyrazinamide; Rifampin; Streptomycin; Treatment Outcome; Tuberculosis, Pulmonary	2002
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. American journal of respiratory and critical care medicine, 2006, Apr-15, Volume: 173, Issue:8 Topics: Adult; Antitubercular Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Incidence; Isoniazid; Male; Pyrazinamide; Retrospective Studies; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary	2006
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17 Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; HIV Seropositivity; Humans; Isoniazid; Kaplan-Meier Estimate; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult	2014
Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2015, Volume: 19, Issue:7 Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Male; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; South Africa; Sputum; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult	2015
Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016, Volume: 20, Issue:6 Topics: Antitubercular Agents; Decision Support Techniques; Ethambutol; Humans; Isoniazid; Markov Chains; Pyrazinamide; Recurrence; Rifampin; Treatment Outcome; Tuberculosis	2016
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. PloS one, 2016, Volume: 11, Issue:5 Topics: Adult; Antitubercular Agents; Case-Control Studies; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary	2016
Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial. BMC infectious diseases, 2023, May-08, Volume: 23, Issue:1 Topics: Clinical Trials, Phase II as Topic; Humans; Isoniazid; Moxifloxacin; Multicenter Studies as Topic; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis	2023

Other Studies

19 other study(ies) available for pyrazinamide and rifapentine

Article	Year
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
[Activity of intermittently administered rifampicin and cyclopentyl rifamycin (or DL473) on experimental tuberculosis in the mouse]. Revue francaise des maladies respiratoires, 1983, Volume: 11, Issue:6 Topics: Animals; DNA-Directed RNA Polymerases; Drug Therapy, Combination; Female; Isoniazid; Mice; Pyrazinamide; Rifampin; Streptomycin; Tuberculosis	1983
Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. American journal of respiratory and critical care medicine, 1994, Volume: 150, Issue:5 Pt 1 Topics: Animals; Antitubercular Agents; Colony-Forming Units Assay; Drug Therapy, Combination; Female; Immunity; Isoniazid; Mice; Mice, Nude; Pyrazinamide; Rifampin; Tuberculosis	1994
Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:10 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Isoniazid; Mice; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Rifamycins; Tuberculosis	1999
Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens. American journal of respiratory and critical care medicine, 2000, Volume: 161, Issue:5 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Ethambutol; Female; Isoniazid; Lung; Mice; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Spleen; Streptomycin; Tuberculosis	2000
Tuberculosis treatment: dangerous regimens? The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2001, Volume: 5, Issue:1 Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Thioacetazone; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; World Health Organization	2001
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. American journal of respiratory and critical care medicine, 2006, Jul-01, Volume: 174, Issue:1 Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Pyrazinamide; Quinolines; Rifampin; Tuberculosis, Pulmonary	2006
Short-course regimens for latent tuberculosis: what is ready for prime time? Enfermedades infecciosas y microbiologia clinica, 2007, Volume: 25, Issue:5 Topics: Antitubercular Agents; Humans; Isoniazid; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis; Virus Latency	2007
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS medicine, 2007, Volume: 4, Issue:12 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Secondary Prevention; Time Factors; Tuberculosis	2007
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? American journal of respiratory and critical care medicine, 2008, Nov-01, Volume: 178, Issue:9 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Pyrazinamide; Quinolines; Recurrence; Rifampin; Time Factors; Treatment Outcome; Tuberculosis	2008
A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. American journal of respiratory and critical care medicine, 2009, Jan-01, Volume: 179, Issue:1 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Female; Lung; Mice; Pyrazinamide; Quinolines; Rifampin; Tuberculosis	2009
Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tuberculosis	2010
Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. American journal of respiratory and critical care medicine, 2011, May-01, Volume: 183, Issue:9 Topics: Animals; Anti-Inflammatory Agents; Antibiotics, Antitubercular; Antitubercular Agents; Cortisone; Disease Models, Animal; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Mice, Nude; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Secondary Prevention; Time Factors; Tuberculosis, Pulmonary	2011
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6 Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2012
Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:7 Topics: Animals; Antitubercular Agents; Female; Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis	2012
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:8 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Isoniazid; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide; Random Allocation; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary	2012
Silicotuberculosis with oesophagobronchial fistulas and broncholithiasis: a case report. The Journal of international medical research, 2018, Volume: 46, Issue:2 Topics: Aged; Antibiotics, Antitubercular; Bronchial Fistula; Esophageal Fistula; Esophagoscopy; Female; Humans; Isoniazid; Lithiasis; Pyrazinamide; Rifampin; Silicotuberculosis; Stents; Treatment Outcome	2018
Improving treatment outcome assessment in a mouse tuberculosis model. Scientific reports, 2018, 04-09, Volume: 8, Issue:1 Topics: Administration, Oral; Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Genotype; Humans; Mice; Mice, Inbred BALB C; Models, Theoretical; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Treatment Outcome; Tuberculosis	2018
Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022. MMWR. Morbidity and mortality weekly report, 2022, Feb-25, Volume: 71, Issue:8 Topics: Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis, Pulmonary; United States	2022